Exosome-disrupting peptides for cancer immunotherapy
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Extracellular vesicles in disease · Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (10)
Show source-provided references
1. Han, Y., Liu, D. & Li, L. Am. J. Cancer Res. 10, 727–742 (2020).
2. Tumeh, P. C. et al. Nature 515, 568–571 (2014).10.1038/nature13954 ↗
3. Yi, M. et al. Mol. Cancer 17, 1–14 (2018).10.1186/s12943-018-0864-3 ↗
4. Chen, G. et al. Nature 560, 382–386 (2018).10.1038/s41586-018-0392-8 ↗
5. Poggio, M. et al. Cell 177, 414–427.e413 (2019).10.1016/j.cell.2019.02.016 ↗
6. Zhang, H., Lu, J., Liu, J., Zhang, G. & Lu, A. J. Enzyme Inhib. Med. Chem. 35, 1322–1330 (2020).10.1080/14756366.2020.1754814 ↗
7. Ostrowski, M. et al. Nat. Cell Biol. 12, 19–30 (2010).10.1038/ncb2000 ↗
8. Jackman, J. A. et al. Nat. Mater. 17, 971–977 (2018).10.1038/s41563-018-0194-2 ↗
9. Shin, S. et al. Nat. Mater. https://doi.org/10.1038/s41563-023-01515-2 (2023).10.1038/s41563-023-01515-2 ↗
10. Papadaki, M. A. et al. Cancers 12, 376 (2020).10.3390/cancers12020376 ↗